Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DefINe trial of deferiprone in neuroferritinopathy
ISRCTN15571700Phase 2Completed
- Sponsor
- Cambridge Clinical Trials Unit
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in neuroferritinopathy (NBIA3) comparing Deferiprone with Placebo (2 arms). Primary endpoint: Change in mean thalamic T2* relaxation rate at 12 months. Started Jun 2024; status: completed.
02
Drugs
deferiprone
03
Conditions
neuroferritinopathy (NBIA3)
Beyond the preview
Go deeper on ISRCTN15571700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15571700.